Key Drivers
- Margin Recovery
- Negative Cash Flow
- Strong Liquidity
AIAI Summary
OPKO is shifting from a discounted diagnostics stock to a milestone-driven therapeutics and royalty story, making BioReference's ability to reach breakeven and materially reduce cash burn the critical near-term validation point; investors should treat ModeX as high-upside optionality until clinical data emerge and avoid relying on EBITDA alone.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Negative Cash Flow
- •Strong Liquidity
OPK's quarterly turnaround in margins and EBITDA is encouraging, but persistent cash burn, declining cash, and asset-quality risks warrant caution despite trading below book value.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance test
- •Momentum intact
OPK gained 14% over the last month with higher lows and healthy momentum, but a break above $1.69 is needed to confirm upside while holding $1.56–$1.59 support remains critical.
Sharp reversal from $1.69 to the $1.49–$1.57 area
Sentiment & News
Key News Insights:
- •Therapeutics Pivot
- •Diagnostics Streamlining
- •Share Price Pressure
OPKO is prioritizing therapeutic pipeline development and partnerships while restructuring diagnostics, but recent share weakness tempers optimism despite new institutional buying.
Pipeline catalysts and capital deployment could support longer-term upside, though near-term execution and market sentiment remain key risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings